Description

According to our latest research, the global Humanized Monoclonal Antibody Drugs market size will reach USD 263525 million in 2031, growing at a CAGR of 10.1% over the analysis period.

Humanized monoclonal antibody drugs are therapeutic antibodies that are predominantly derived from human antibody structures, but with small portions—typically the complementarity-determining regions (CDRs)—originating from non-human species, such as mice. These drugs are engineered through recombinant DNA technology to reduce immunogenicity while maintaining high specificity and binding affinity to the target antigen. Humanized antibodies are widely used to treat cancers, autoimmune diseases, and inflammatory conditions.

This report is a detailed and comprehensive analysis for global Humanized Monoclonal Antibody Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:
Global Humanized Monoclonal Antibody Drugs market size and forecasts, in consumption value ($ Million), 2020-2031
Global Humanized Monoclonal Antibody Drugs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Humanized Monoclonal Antibody Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Humanized Monoclonal Antibody Drugs market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Humanized Monoclonal Antibody Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Humanized Monoclonal Antibody Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck & Co, AbbVie, Eli Lilly & Co, Roche, Takeda, GlaxoSmithKline, UCB, AstraZeneca, Biogen, Gilead Sciences, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation
Humanized Monoclonal Antibody Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Pembrolizumab
    Risenqizumab
    Orelizumab
    Ixekizumab
    Vedolizumab
    Bevacizumab
    Omalizumab
    Farisimab
    Trastuzumab
    Other

Market segment by Application
    Cancers
    Autoimmune Diseases
    Inflammatory Condition

Market segment by players, this report covers
    Merck & Co
    AbbVie
    Eli Lilly & Co
    Roche
    Takeda
    GlaxoSmithKline
    UCB
    AstraZeneca
    Biogen
    Gilead Sciences
    Novartis
    Teva
    Qilu Pharma
    Sun Pharmaceutical
    Johnson & Johnson
    Beigene
    Pfizer
    Innovent Bio

Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Humanized Monoclonal Antibody Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Humanized Monoclonal Antibody Drugs, with revenue, gross margin, and global market share of Humanized Monoclonal Antibody Drugs from 2020 to 2025.
Chapter 3, the Humanized Monoclonal Antibody Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Humanized Monoclonal Antibody Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Humanized Monoclonal Antibody Drugs.
Chapter 13, to describe Humanized Monoclonal Antibody Drugs research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Humanized Monoclonal Antibody Drugs by Type
        1.3.1 Overview: Global Humanized Monoclonal Antibody Drugs Market Size by Type: 2020 Versus 2024 Versus 2031
        1.3.2 Global Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Type in 2024
        1.3.3 Pembrolizumab
        1.3.4 Risenqizumab
        1.3.5 Orelizumab
        1.3.6 Ixekizumab
        1.3.7 Vedolizumab
        1.3.8 Bevacizumab
        1.3.9 Omalizumab
        1.3.10 Farisimab
        1.3.11 Trastuzumab
    1.4 Global Humanized Monoclonal Antibody Drugs Market by Application
        1.4.1 Overview: Global Humanized Monoclonal Antibody Drugs Market Size by Application: 2020 Versus 2024 Versus 2031
        1.4.2 Cancers
        1.4.3 Autoimmune Diseases
        1.4.4 Inflammatory Condition
    1.5 Global Humanized Monoclonal Antibody Drugs Market Size & Forecast
    1.6 Global Humanized Monoclonal Antibody Drugs Market Size and Forecast by Region
        1.6.1 Global Humanized Monoclonal Antibody Drugs Market Size by Region: 2020 VS 2024 VS 2031
        1.6.2 Global Humanized Monoclonal Antibody Drugs Market Size by Region, (2020-2031)
        1.6.3 North America Humanized Monoclonal Antibody Drugs Market Size and Prospect (2020-2031)
        1.6.4 Europe Humanized Monoclonal Antibody Drugs Market Size and Prospect (2020-2031)
        1.6.5 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size and Prospect (2020-2031)
        1.6.6 South America Humanized Monoclonal Antibody Drugs Market Size and Prospect (2020-2031)
        1.6.7 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size and Prospect (2020-2031)

2 Company Profiles
    2.1 Merck & Co
        2.1.1 Merck & Co Details
        2.1.2 Merck & Co Major Business
        2.1.3 Merck & Co Humanized Monoclonal Antibody Drugs Product and Solutions
        2.1.4 Merck & Co Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.1.5 Merck & Co Recent Developments and Future Plans
    2.2 AbbVie
        2.2.1 AbbVie Details
        2.2.2 AbbVie Major Business
        2.2.3 AbbVie Humanized Monoclonal Antibody Drugs Product and Solutions
        2.2.4 AbbVie Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.2.5 AbbVie Recent Developments and Future Plans
    2.3 Eli Lilly & Co
        2.3.1 Eli Lilly & Co Details
        2.3.2 Eli Lilly & Co Major Business
        2.3.3 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product and Solutions
        2.3.4 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.3.5 Eli Lilly & Co Recent Developments and Future Plans
    2.4 Roche
        2.4.1 Roche Details
        2.4.2 Roche Major Business
        2.4.3 Roche Humanized Monoclonal Antibody Drugs Product and Solutions
        2.4.4 Roche Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.4.5 Roche Recent Developments and Future Plans
    2.5 Takeda
        2.5.1 Takeda Details
        2.5.2 Takeda Major Business
        2.5.3 Takeda Humanized Monoclonal Antibody Drugs Product and Solutions
        2.5.4 Takeda Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.5.5 Takeda Recent Developments and Future Plans
    2.6 GlaxoSmithKline
        2.6.1 GlaxoSmithKline Details
        2.6.2 GlaxoSmithKline Major Business
        2.6.3 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product and Solutions
        2.6.4 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.6.5 GlaxoSmithKline Recent Developments and Future Plans
    2.7 UCB
        2.7.1 UCB Details
        2.7.2 UCB Major Business
        2.7.3 UCB Humanized Monoclonal Antibody Drugs Product and Solutions
        2.7.4 UCB Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.7.5 UCB Recent Developments and Future Plans
    2.8 AstraZeneca
        2.8.1 AstraZeneca Details
        2.8.2 AstraZeneca Major Business
        2.8.3 AstraZeneca Humanized Monoclonal Antibody Drugs Product and Solutions
        2.8.4 AstraZeneca Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.8.5 AstraZeneca Recent Developments and Future Plans
    2.9 Biogen
        2.9.1 Biogen Details
        2.9.2 Biogen Major Business
        2.9.3 Biogen Humanized Monoclonal Antibody Drugs Product and Solutions
        2.9.4 Biogen Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.9.5 Biogen Recent Developments and Future Plans
    2.10 Gilead Sciences
        2.10.1 Gilead Sciences Details
        2.10.2 Gilead Sciences Major Business
        2.10.3 Gilead Sciences Humanized Monoclonal Antibody Drugs Product and Solutions
        2.10.4 Gilead Sciences Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.10.5 Gilead Sciences Recent Developments and Future Plans
    2.11 Novartis
        2.11.1 Novartis Details
        2.11.2 Novartis Major Business
        2.11.3 Novartis Humanized Monoclonal Antibody Drugs Product and Solutions
        2.11.4 Novartis Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.11.5 Novartis Recent Developments and Future Plans
    2.12 Teva
        2.12.1 Teva Details
        2.12.2 Teva Major Business
        2.12.3 Teva Humanized Monoclonal Antibody Drugs Product and Solutions
        2.12.4 Teva Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.12.5 Teva Recent Developments and Future Plans
    2.13 Qilu Pharma
        2.13.1 Qilu Pharma Details
        2.13.2 Qilu Pharma Major Business
        2.13.3 Qilu Pharma Humanized Monoclonal Antibody Drugs Product and Solutions
        2.13.4 Qilu Pharma Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.13.5 Qilu Pharma Recent Developments and Future Plans
    2.14 Sun Pharmaceutical
        2.14.1 Sun Pharmaceutical Details
        2.14.2 Sun Pharmaceutical Major Business
        2.14.3 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product and Solutions
        2.14.4 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.14.5 Sun Pharmaceutical Recent Developments and Future Plans
    2.15 Johnson & Johnson
        2.15.1 Johnson & Johnson Details
        2.15.2 Johnson & Johnson Major Business
        2.15.3 Johnson & Johnson Humanized Monoclonal Antibody Drugs Product and Solutions
        2.15.4 Johnson & Johnson Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.15.5 Johnson & Johnson Recent Developments and Future Plans
    2.16 Beigene
        2.16.1 Beigene Details
        2.16.2 Beigene Major Business
        2.16.3 Beigene Humanized Monoclonal Antibody Drugs Product and Solutions
        2.16.4 Beigene Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.16.5 Beigene Recent Developments and Future Plans
    2.17 Pfizer
        2.17.1 Pfizer Details
        2.17.2 Pfizer Major Business
        2.17.3 Pfizer Humanized Monoclonal Antibody Drugs Product and Solutions
        2.17.4 Pfizer Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.17.5 Pfizer Recent Developments and Future Plans
    2.18 Innovent Bio
        2.18.1 Innovent Bio Details
        2.18.2 Innovent Bio Major Business
        2.18.3 Innovent Bio Humanized Monoclonal Antibody Drugs Product and Solutions
        2.18.4 Innovent Bio Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
        2.18.5 Innovent Bio Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Humanized Monoclonal Antibody Drugs Revenue and Share by Players (2020-2025)
    3.2 Market Share Analysis (2024)
        3.2.1 Market Share of Humanized Monoclonal Antibody Drugs by Company Revenue
        3.2.2 Top 3 Humanized Monoclonal Antibody Drugs Players Market Share in 2024
        3.2.3 Top 6 Humanized Monoclonal Antibody Drugs Players Market Share in 2024
    3.3 Humanized Monoclonal Antibody Drugs Market: Overall Company Footprint Analysis
        3.3.1 Humanized Monoclonal Antibody Drugs Market: Region Footprint
        3.3.2 Humanized Monoclonal Antibody Drugs Market: Company Product Type Footprint
        3.3.3 Humanized Monoclonal Antibody Drugs Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Humanized Monoclonal Antibody Drugs Consumption Value and Market Share by Type (2020-2025)
    4.2 Global Humanized Monoclonal Antibody Drugs Market Forecast by Type (2026-2031)

5 Market Size Segment by Application
    5.1 Global Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Application (2020-2025)
    5.2 Global Humanized Monoclonal Antibody Drugs Market Forecast by Application (2026-2031)

6 North America
    6.1 North America Humanized Monoclonal Antibody Drugs Consumption Value by Type (2020-2031)
    6.2 North America Humanized Monoclonal Antibody Drugs Market Size by Application (2020-2031)
    6.3 North America Humanized Monoclonal Antibody Drugs Market Size by Country
        6.3.1 North America Humanized Monoclonal Antibody Drugs Consumption Value by Country (2020-2031)
        6.3.2 United States Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        6.3.3 Canada Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        6.3.4 Mexico Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)

7 Europe
    7.1 Europe Humanized Monoclonal Antibody Drugs Consumption Value by Type (2020-2031)
    7.2 Europe Humanized Monoclonal Antibody Drugs Consumption Value by Application (2020-2031)
    7.3 Europe Humanized Monoclonal Antibody Drugs Market Size by Country
        7.3.1 Europe Humanized Monoclonal Antibody Drugs Consumption Value by Country (2020-2031)
        7.3.2 Germany Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        7.3.3 France Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        7.3.4 United Kingdom Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        7.3.5 Russia Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        7.3.6 Italy Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)

8 Asia-Pacific
    8.1 Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value by Type (2020-2031)
    8.2 Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value by Application (2020-2031)
    8.3 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size by Region
        8.3.1 Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value by Region (2020-2031)
        8.3.2 China Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        8.3.3 Japan Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        8.3.4 South Korea Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        8.3.5 India Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        8.3.6 Southeast Asia Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        8.3.7 Australia Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)

9 South America
    9.1 South America Humanized Monoclonal Antibody Drugs Consumption Value by Type (2020-2031)
    9.2 South America Humanized Monoclonal Antibody Drugs Consumption Value by Application (2020-2031)
    9.3 South America Humanized Monoclonal Antibody Drugs Market Size by Country
        9.3.1 South America Humanized Monoclonal Antibody Drugs Consumption Value by Country (2020-2031)
        9.3.2 Brazil Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        9.3.3 Argentina Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)

10 Middle East & Africa
    10.1 Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value by Type (2020-2031)
    10.2 Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value by Application (2020-2031)
    10.3 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country
        10.3.1 Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value by Country (2020-2031)
        10.3.2 Turkey Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        10.3.3 Saudi Arabia Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)
        10.3.4 UAE Humanized Monoclonal Antibody Drugs Market Size and Forecast (2020-2031)

11 Market Dynamics
    11.1 Humanized Monoclonal Antibody Drugs Market Drivers
    11.2 Humanized Monoclonal Antibody Drugs Market Restraints
    11.3 Humanized Monoclonal Antibody Drugs Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Humanized Monoclonal Antibody Drugs Industry Chain
    12.2 Humanized Monoclonal Antibody Drugs Upstream Analysis
    12.3 Humanized Monoclonal Antibody Drugs Midstream Analysis
    12.4 Humanized Monoclonal Antibody Drugs Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Humanized Monoclonal Antibody Drugs Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
 Table 2. Global Humanized Monoclonal Antibody Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
 Table 3. Global Humanized Monoclonal Antibody Drugs Consumption Value by Region (2020-2025) & (USD Million)
 Table 4. Global Humanized Monoclonal Antibody Drugs Consumption Value by Region (2026-2031) & (USD Million)
 Table 5. Merck & Co Company Information, Head Office, and Major Competitors
 Table 6. Merck & Co Major Business
 Table 7. Merck & Co Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 8. Merck & Co Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 9. Merck & Co Recent Developments and Future Plans
 Table 10. AbbVie Company Information, Head Office, and Major Competitors
 Table 11. AbbVie Major Business
 Table 12. AbbVie Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 13. AbbVie Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 14. AbbVie Recent Developments and Future Plans
 Table 15. Eli Lilly & Co Company Information, Head Office, and Major Competitors
 Table 16. Eli Lilly & Co Major Business
 Table 17. Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 18. Eli Lilly & Co Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 19. Roche Company Information, Head Office, and Major Competitors
 Table 20. Roche Major Business
 Table 21. Roche Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 22. Roche Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 23. Roche Recent Developments and Future Plans
 Table 24. Takeda Company Information, Head Office, and Major Competitors
 Table 25. Takeda Major Business
 Table 26. Takeda Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 27. Takeda Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 28. Takeda Recent Developments and Future Plans
 Table 29. GlaxoSmithKline Company Information, Head Office, and Major Competitors
 Table 30. GlaxoSmithKline Major Business
 Table 31. GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 32. GlaxoSmithKline Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 33. GlaxoSmithKline Recent Developments and Future Plans
 Table 34. UCB Company Information, Head Office, and Major Competitors
 Table 35. UCB Major Business
 Table 36. UCB Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 37. UCB Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 38. UCB Recent Developments and Future Plans
 Table 39. AstraZeneca Company Information, Head Office, and Major Competitors
 Table 40. AstraZeneca Major Business
 Table 41. AstraZeneca Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 42. AstraZeneca Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 43. AstraZeneca Recent Developments and Future Plans
 Table 44. Biogen Company Information, Head Office, and Major Competitors
 Table 45. Biogen Major Business
 Table 46. Biogen Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 47. Biogen Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 48. Biogen Recent Developments and Future Plans
 Table 49. Gilead Sciences Company Information, Head Office, and Major Competitors
 Table 50. Gilead Sciences Major Business
 Table 51. Gilead Sciences Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 52. Gilead Sciences Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 53. Gilead Sciences Recent Developments and Future Plans
 Table 54. Novartis Company Information, Head Office, and Major Competitors
 Table 55. Novartis Major Business
 Table 56. Novartis Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 57. Novartis Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 58. Novartis Recent Developments and Future Plans
 Table 59. Teva Company Information, Head Office, and Major Competitors
 Table 60. Teva Major Business
 Table 61. Teva Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 62. Teva Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 63. Teva Recent Developments and Future Plans
 Table 64. Qilu Pharma Company Information, Head Office, and Major Competitors
 Table 65. Qilu Pharma Major Business
 Table 66. Qilu Pharma Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 67. Qilu Pharma Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 68. Qilu Pharma Recent Developments and Future Plans
 Table 69. Sun Pharmaceutical Company Information, Head Office, and Major Competitors
 Table 70. Sun Pharmaceutical Major Business
 Table 71. Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 72. Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 73. Sun Pharmaceutical Recent Developments and Future Plans
 Table 74. Johnson & Johnson Company Information, Head Office, and Major Competitors
 Table 75. Johnson & Johnson Major Business
 Table 76. Johnson & Johnson Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 77. Johnson & Johnson Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 78. Johnson & Johnson Recent Developments and Future Plans
 Table 79. Beigene Company Information, Head Office, and Major Competitors
 Table 80. Beigene Major Business
 Table 81. Beigene Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 82. Beigene Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 83. Beigene Recent Developments and Future Plans
 Table 84. Pfizer Company Information, Head Office, and Major Competitors
 Table 85. Pfizer Major Business
 Table 86. Pfizer Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 87. Pfizer Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 88. Pfizer Recent Developments and Future Plans
 Table 89. Innovent Bio Company Information, Head Office, and Major Competitors
 Table 90. Innovent Bio Major Business
 Table 91. Innovent Bio Humanized Monoclonal Antibody Drugs Product and Solutions
 Table 92. Innovent Bio Humanized Monoclonal Antibody Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 93. Innovent Bio Recent Developments and Future Plans
 Table 94. Global Humanized Monoclonal Antibody Drugs Revenue (USD Million) by Players (2020-2025)
 Table 95. Global Humanized Monoclonal Antibody Drugs Revenue Share by Players (2020-2025)
 Table 96. Breakdown of Humanized Monoclonal Antibody Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
 Table 97. Market Position of Players in Humanized Monoclonal Antibody Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
 Table 98. Head Office of Key Humanized Monoclonal Antibody Drugs Players
 Table 99. Humanized Monoclonal Antibody Drugs Market: Company Product Type Footprint
 Table 100. Humanized Monoclonal Antibody Drugs Market: Company Product Application Footprint
 Table 101. Humanized Monoclonal Antibody Drugs New Market Entrants and Barriers to Market Entry
 Table 102. Humanized Monoclonal Antibody Drugs Mergers, Acquisition, Agreements, and Collaborations
 Table 103. Global Humanized Monoclonal Antibody Drugs Consumption Value (USD Million) by Type (2020-2025)
 Table 104. Global Humanized Monoclonal Antibody Drugs Consumption Value Share by Type (2020-2025)
 Table 105. Global Humanized Monoclonal Antibody Drugs Consumption Value Forecast by Type (2026-2031)
 Table 106. Global Humanized Monoclonal Antibody Drugs Consumption Value by Application (2020-2025)
 Table 107. Global Humanized Monoclonal Antibody Drugs Consumption Value Forecast by Application (2026-2031)
 Table 108. North America Humanized Monoclonal Antibody Drugs Consumption Value by Type (2020-2025) & (USD Million)
 Table 109. North America Humanized Monoclonal Antibody Drugs Consumption Value by Type (2026-2031) & (USD Million)
 Table 110. North America Humanized Monoclonal Antibody Drugs Consumption Value by Application (2020-2025) & (USD Million)
 Table 111. North America Humanized Monoclonal Antibody Drugs Consumption Value by Application (2026-2031) & (USD Million)
 Table 112. North America Humanized Monoclonal Antibody Drugs Consumption Value by Country (2020-2025) & (USD Million)
 Table 113. North America Humanized Monoclonal Antibody Drugs Consumption Value by Country (2026-2031) & (USD Million)
 Table 114. Europe Humanized Monoclonal Antibody Drugs Consumption Value by Type (2020-2025) & (USD Million)
 Table 115. Europe Humanized Monoclonal Antibody Drugs Consumption Value by Type (2026-2031) & (USD Million)
 Table 116. Europe Humanized Monoclonal Antibody Drugs Consumption Value by Application (2020-2025) & (USD Million)
 Table 117. Europe Humanized Monoclonal Antibody Drugs Consumption Value by Application (2026-2031) & (USD Million)
 Table 118. Europe Humanized Monoclonal Antibody Drugs Consumption Value by Country (2020-2025) & (USD Million)
 Table 119. Europe Humanized Monoclonal Antibody Drugs Consumption Value by Country (2026-2031) & (USD Million)
 Table 120. Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value by Type (2020-2025) & (USD Million)
 Table 121. Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value by Type (2026-2031) & (USD Million)
 Table 122. Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value by Application (2020-2025) & (USD Million)
 Table 123. Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value by Application (2026-2031) & (USD Million)
 Table 124. Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value by Region (2020-2025) & (USD Million)
 Table 125. Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value by Region (2026-2031) & (USD Million)
 Table 126. South America Humanized Monoclonal Antibody Drugs Consumption Value by Type (2020-2025) & (USD Million)
 Table 127. South America Humanized Monoclonal Antibody Drugs Consumption Value by Type (2026-2031) & (USD Million)
 Table 128. South America Humanized Monoclonal Antibody Drugs Consumption Value by Application (2020-2025) & (USD Million)
 Table 129. South America Humanized Monoclonal Antibody Drugs Consumption Value by Application (2026-2031) & (USD Million)
 Table 130. South America Humanized Monoclonal Antibody Drugs Consumption Value by Country (2020-2025) & (USD Million)
 Table 131. South America Humanized Monoclonal Antibody Drugs Consumption Value by Country (2026-2031) & (USD Million)
 Table 132. Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value by Type (2020-2025) & (USD Million)
 Table 133. Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value by Type (2026-2031) & (USD Million)
 Table 134. Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value by Application (2020-2025) & (USD Million)
 Table 135. Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value by Application (2026-2031) & (USD Million)
 Table 136. Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value by Country (2020-2025) & (USD Million)
 Table 137. Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value by Country (2026-2031) & (USD Million)
 Table 138. Global Key Players of Humanized Monoclonal Antibody Drugs Upstream (Raw Materials)
 Table 139. Global Humanized Monoclonal Antibody Drugs Typical Customers


List of Figures
 Figure 1. Humanized Monoclonal Antibody Drugs Picture
 Figure 2. Global Humanized Monoclonal Antibody Drugs Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
 Figure 3. Global Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Type in 2024
 Figure 4. Pembrolizumab
 Figure 5. Risenqizumab
 Figure 6. Orelizumab
 Figure 7. Ixekizumab
 Figure 8. Vedolizumab
 Figure 9. Bevacizumab
 Figure 10. Omalizumab
 Figure 11. Farisimab
 Figure 12. Trastuzumab
 Figure 13. Global Humanized Monoclonal Antibody Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
 Figure 14. Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Application in 2024
 Figure 15. Cancers Picture
 Figure 16. Autoimmune Diseases Picture
 Figure 17. Inflammatory Condition Picture
 Figure 18. Global Humanized Monoclonal Antibody Drugs Consumption Value, (USD Million): 2020 & 2024 & 2031
 Figure 19. Global Humanized Monoclonal Antibody Drugs Consumption Value and Forecast (2020-2031) & (USD Million)
 Figure 20. Global Market Humanized Monoclonal Antibody Drugs Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
 Figure 21. Global Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Region (2020-2031)
 Figure 22. Global Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Region in 2024
 Figure 23. North America Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 24. Europe Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 25. Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 26. South America Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 27. Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 28. Company Three Recent Developments and Future Plans
 Figure 29. Global Humanized Monoclonal Antibody Drugs Revenue Share by Players in 2024
 Figure 30. Humanized Monoclonal Antibody Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
 Figure 31. Market Share of Humanized Monoclonal Antibody Drugs by Player Revenue in 2024
 Figure 32. Top 3 Humanized Monoclonal Antibody Drugs Players Market Share in 2024
 Figure 33. Top 6 Humanized Monoclonal Antibody Drugs Players Market Share in 2024
 Figure 34. Global Humanized Monoclonal Antibody Drugs Consumption Value Share by Type (2020-2025)
 Figure 35. Global Humanized Monoclonal Antibody Drugs Market Share Forecast by Type (2026-2031)
 Figure 36. Global Humanized Monoclonal Antibody Drugs Consumption Value Share by Application (2020-2025)
 Figure 37. Global Humanized Monoclonal Antibody Drugs Market Share Forecast by Application (2026-2031)
 Figure 38. North America Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Type (2020-2031)
 Figure 39. North America Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Application (2020-2031)
 Figure 40. North America Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Country (2020-2031)
 Figure 41. United States Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 42. Canada Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 43. Mexico Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 44. Europe Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Type (2020-2031)
 Figure 45. Europe Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Application (2020-2031)
 Figure 46. Europe Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Country (2020-2031)
 Figure 47. Germany Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 48. France Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 49. United Kingdom Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 50. Russia Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 51. Italy Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 52. Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Type (2020-2031)
 Figure 53. Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Application (2020-2031)
 Figure 54. Asia-Pacific Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Region (2020-2031)
 Figure 55. China Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 56. Japan Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 57. South Korea Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 58. India Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 59. Southeast Asia Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 60. Australia Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 61. South America Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Type (2020-2031)
 Figure 62. South America Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Application (2020-2031)
 Figure 63. South America Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Country (2020-2031)
 Figure 64. Brazil Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 65. Argentina Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 66. Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Type (2020-2031)
 Figure 67. Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Application (2020-2031)
 Figure 68. Middle East & Africa Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Country (2020-2031)
 Figure 69. Turkey Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 70. Saudi Arabia Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 71. UAE Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
 Figure 72. Humanized Monoclonal Antibody Drugs Market Drivers
 Figure 73. Humanized Monoclonal Antibody Drugs Market Restraints
 Figure 74. Humanized Monoclonal Antibody Drugs Market Trends
 Figure 75. Porters Five Forces Analysis
 Figure 76. Humanized Monoclonal Antibody Drugs Industrial Chain
 Figure 77. Methodology
 Figure 78. Research Process and Data Source

Companies Mentioned

Merck & Co
AbbVie
Eli Lilly & Co
Roche
Takeda
GlaxoSmithKline
UCB
AstraZeneca
Biogen
Gilead Sciences
Novartis
Teva
Qilu Pharma
Sun Pharmaceutical
Johnson & Johnson
Beigene
Pfizer
Innovent Bio